Encellin Partnered With Breakthrough T1D for Diabetes
A new $2.5 million grant will support a clinical study of an immune-protected cell therapy in Canada.
Updated on Sept. 22, 2026 in Diabetes
Live Poll
Should private organizations prioritize funding new clinical research for chronic disease cures?
Encellin has partnered with Breakthrough T1D to advance a novel encapsulated cell replacement therapy for Type 1 Diabetes. The collaboration is supported by a $2.5 million grant awarded through the Industry Discovery and Development Partnership program.
Why it matters
This partnership aims to develop cell replacement therapies capable of functioning without the need for systemic immunosuppression. The project focuses on testing an implant that excludes immune cells while supporting donor islet survival.
The study will utilize the ENCRT-103-hPI implant, following a previous Phase 1 trial, NCT06408311, which confirmed non-fibrotic tissue integration. Researchers will now move to clinical trial NCT07680673 to test the technology in Canada.
The players
Encellin
A San Francisco-based company that develops Encapsulated Cell Replacement Therapy to treat chronic conditions.
Breakthrough T1D
A New York-based organization that funds research to cure and treat Type 1 Diabetes.
The details
The upcoming clinical study, designated NCT07680673, will evaluate the safety, tolerability, and local tissue response of the implant. Researchers are specifically testing the membrane's ability to protect donor islets while maintaining vascular integration within the body.
Timeline
On September 22, 2026, Encellin announced the partnership and the new funding award.
The Breakthrough T1D grant provides support over a 24-month period.
The Big Picture
This collaboration follows the model established by the Industry Discovery and Development Partnership program to bridge the gap between academic innovation and clinical application. By securing this grant, the research project aligns with global efforts to transition diabetes care away from systemic immunosuppressive drugs.
This research could eventually offer patients with Type 1 Diabetes an alternative to traditional, life-long immunosuppressant medication. While the trial is currently in the testing phase, successful results may pave the way for new long-term treatment options.
The takeaway
The development of non-systemic immunosuppressive therapies represents a significant shift in how chronic autoimmune diseases are managed. Patients should look for future updates regarding the clinical outcomes of the ENCRT-103-hPI implant program.
Further reading
Learn more about the latest innovations in Diabetes research and treatment.
Live Poll
Should private organizations prioritize funding new clinical research for chronic disease cures?
